Indeed, results from a post‐hoc analysis of The Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF‐TIMI 48) trial revealed that overweight and obese patients with AF had a lower risk of stroke/systemic embolism and mortality.9 The gene discussed is F10; the disease is atrial fibrillation.